Physician profile
Boris Borodulin
NPI 1770646358
$116,141.58
in general payments reported to CMS, 2019-2025
35 companies · $14K in 2025
The $14K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $13K · 2021: $15K · 2022: $19K · 2023: $26K · 2024: $15K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Food and Beverage: $9,089 · Travel and Lodging: $201 · Education: $91.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,167.50 |
| Food and Beverage | $9,089.29 |
| Travel and Lodging | $200.70 |
| Education | $91.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $73,083.58 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $16,293.32 | 2019-2025 | Rexulti, Abilify Maintena |
| Allergan, INC. | $10,180.42 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $5,032.23 | 2023-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $4,238.74 | 2019-2025 | Trintellix |
| Lundbeck LLC | $1,416.50 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $990.98 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $839.78 | 2023-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $744.32 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $551.65 | 2020-2023 | Austedo Xr, Austedo |
| Bausch Health US, LLC | $372.51 | 2019-2025 | Aplenzin, Wellbutrin |
| Vanda Pharmaceuticals INC. | $307.72 | 2019-2025 | Fanapt |
| Alkermes, INC. | $252.65 | 2021-2025 | Aristada, Lybalvi |
| Corium, LLC | $226.75 | 2022-2024 | Azstarys, Adlarity |
| Supernus Pharmaceuticals, INC. | $223.16 | 2022-2025 | Qelbree, Qelbree |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $183.13 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $181.48 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $139.80 | 2019-2024 | Spravato, Invega Sustenna |
| Neos Therapeutics, LP | $106.34 | 2020-2022 | |
| Noven Therapeutics, LLC | $94.66 | 2020-2022 | |
| Eisai INC. | $83.33 | 2020-2024 | |
| Acadia Pharmaceuticals INC | $79.88 | 2019-2021 | |
| Tris Pharma INC | $78.12 | 2022-2024 | Dyanavel Xr |
| Almatica Pharma LLC | $69.31 | 2021-2024 | Loreev Xr |
| Ironshore Pharmaceuticals INC. | $61.82 | 2024 | |
| Collegium Pharmaceutical, INC. | $60.83 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $55.84 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $51.20 | 2020-2021 | |
| Biogen, INC. | $26.94 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $26.75 | 2021 | |
| Brainsway USA INC | $26.71 | 2019 | |
| Tonix Medicines, INC. | $18.93 | 2025 | Tonmya |
| Owp Pharmaceuticals, INC. | $14.85 | 2025 | Subvenite |
| Sage Therapeutics, LLC | $14.01 | 2024 | |
| Avanir Pharmaceuticals, INC. | $13.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boris Borodulin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.